跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
ON-02
首页
药物
ON-02
ON-02
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
CD5 specific T cell receptor cell or gene therapy
US 12479903 B2
申请人: MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN HELMHOLTZ GEMEINSCHAFT
优先权: 2019
EP
US
WO
5 件公开
Antibodies and their use in the treatment, prevention and diagnosis of a disease associated with SOD1 abnormalities
US 8759029 B2
申请人: JULIEN JEAN-PIERRE
优先权: 2006
US
4 件公开
MAGE-B2-SPECIFIC T-CELL RECEPTORS
EP 4267173 A2
申请人: AMGEN INC
优先权: 2020
EP
US
WO
3 件公开
DCAF4L2-SPECIFIC T-CELL RECEPTORS
EP 4453016 A1
申请人: AMGEN INC
优先权: 2021
EP
US
WO
3 件公开
SINGLE-CHAIN FRAGMENT VARIABLE TARGETING KRAS G12V, CHIMERIC ANTIGEN RECEPTOR, AND USE THEREOF
US 20260108609 A1
申请人: THE FIRST AFFILIATED HOSPITAL OF WANNAN MEDICAL COLLEGE
优先权: 2023
CN
US
WO
3 件公开
Vehicle comprising a distance control system
US 8077024 B2
申请人: LAUFER MARTIN
优先权: 2005
CN
US
3 件公开
High affinity engineered T-cell receptors targeting cmv infected cells
US 12649772 B2
申请人: UNIV TEXAS
优先权: 2019
US
WO
3 件公开
T cell receptors and fusion proteins thereof
US 12065475 B2
申请人: IMMUNOCORE LTD
优先权: 2022
CN
US
2 件公开
T-CELL RECEPTOR THAT TARGETS EGFR MUTATION AND METHODS OF USING THE SAME
US 20260078163 A1
申请人: UNIV TEXAS
优先权: 2022
US
WO
2 件公开
IMPROVED PHOX2B PC-CAR GENERATION BASED ON STRUCTURE AND SATURATION MUTAGENESIS
US 20260243766 A1
申请人: CHILDRENS HOSPITAL PHILADELPHIA
优先权: 2023
US
WO
2 件公开
第 1 / 9 页
上一页
下一页
药物
反馈